Recently, the KRAS G12C inhibitor sotorasib was approved as the world's first drug targeting KRAS, showing efficacy against unresectable advanced or recurrent non‐small cell lung cancer with KRAS G12C mutation‐positive disease that progressed after cancer chemotherapy [19]. This evidence concerns the gene KRAS and cancer.